deucravacitinib治疗SLE的全血转录组分析:TYK2抑制新机制
该研究为PAISLEY 2期试验的事后分析,对363例SLE患者和56名健康志愿者基线和第32周样本行RNA测序,用线性混合效应模型分析差异基因。结果显示deucravacitinib可调节多达2529个基因及干扰素相关基因集,并改变浆细胞、髓系细胞、树突状细胞和调节性T细胞相关基因表达。
要点
- deucravacitinib可调节SLE相关基因表达,包括干扰素调控基因。
- 治疗使浆细胞基因集下降,髓系细胞基因集向正常水平回复。
- 与安慰剂相比,deucravacitinib显著富集树突状细胞群。
核心结论
- deucravacitinib在SLE中引起预期和新的基因表达变化,涉及多条致病通路,支持进一步3期评估。
研究设计与样本
- PAISLEY 2期试验事后分析,对363例SLE患者和56名健康志愿者基线与第32周样本行RNA测序,采用线性混合效应模型和ssGSEA分析。
主要发现
- 基线时SLE患者与健康志愿者间鉴定出527个差异表达基因(log2 fold change >1;校正P < .05)。
- deucravacitinib调节多达2529个基因和SLE相关基因集,包括干扰素调控基因。
- ssGSEA显示deucravacitinib使浆细胞基因集下降、髓系细胞基因集向正常水平回复。
- xCell反卷积显示deucravacitinib组较安慰剂组显著富集树突状细胞群。
- 基线时SLE患者调节性T细胞基因集较健康志愿者增加,deucravacitinib治疗后进一步增加。
关键数值与推荐
- 基线差异表达基因阈值:log2 fold change >1且校正P < .05。
- deucravacitinib调节基因数量最多达2529个。
临床怎么用
- deucravacitinib通过调节干扰素、浆细胞、髓系细胞和树突状细胞等多条通路发挥免疫调节作用。
局限性
- 本文为事后分析,结果需未来研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To further understand the mechanism of action of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY SLE trial. METHODS: RNA sequencing (RNA-seq) was performed on samples collected from baseline to week 32 in 363 patients and 56 healthy volunteers. Pharmacodynamics of differentially expressed genes (DEGs) were analysed with linear mixed-effects models using the statistical software package DREAM (differential expression for repeated measures). Single-sample gene set enrichment analysis (ssGSEA) was performed using MSigDB Hallmark and BloodGen3 gene modules. The xCell R package was used to digitally portray the blood cellular heterogeneity landscape. RESULTS: At baseline, 527 DEGs were identified in patients with SLE vs healthy volunteers (log2 fold change >1; adjusted P < .05). Deucravacitinib modulated up to 2529 genes and SLE-relevant gene sets, including interferon-regulated genes. ssGSEA showed that plasma cell gene sets decreased and myeloid cell gene sets reverted towards normal levels with deucravacitinib; xCell deconvolution revealed significant enrichment of dendritic cell populations with deucravacitinib vs placebo. At baseline, regulatory T-cell gene sets were increased in patients with SLE vs healthy volunteers and further increased with deucravacitinib. There were some variable, dose-dependent increases in naïve and memory B lymphocytes. CONCLUSIONS: Whole blood transcriptome profiling via RNA-seq revealed both expected and novel gene expression changes with deucravacitinib across multiple pathogenic pathways. These data demonstrate successful targeting of pathophysiologic immune mechanisms that should be validated in future studies and support continued evaluation of deucravacitinib in the phase 3 POETYK SLE trials.
引用
- Vital E, Wu C, Kahlenberg JM, et al. Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial. Ann Rheum Dis. 2026. PMID: 42115051. doi:10.1016/j.ard.2026.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。